my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
30-04-2012: Dr. Dirk Ehle has been appointed Head of the Animal Health Division of Bayer HealthCare AG effective May 1, 2012. The 42-year-old succeeds Dr. Jean-Luc Lowinski, who is leaving the company at his own request. As divisional head, Ehle will also be member of the Bayer HealthCare Executive Committee.
Dirk Ehle studied law at the universities in Freiburg (Germany), Aix-en-Provence (France), Würzburg (Germany) and New York (USA). He joined Bayer as an attorney in the Legal Department in 2001. In 2006, Ehle transferred to the Corporate Center, where he was assistant to the Board of Management and was later in charge of Public Affairs. In 2010, Dirk Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Head of Bayer HealthCare in Poland.
Dirk Ehle is married with three children.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Bayer’s Riociguat submitted for regulatory approval in the U.S. and EU
Bayer HealthCare has submitted the oral investigational drug Riociguat to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for regulatory approval in the United States and in the European Union. “These regulatory ... more
QIAGEN and Bayer HealthCare announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular info ... more
Anti-Cancer Project Originating from LDC Reaches Next Milestone
The Lead Discovery Center GmbH (LDC) announced that a kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) last year, has reached an important transition milestone. Bayer has successfully advanced this kinase inhibitor program into pre-clinical development with the goal of ... more
Bayer Pharmaceutical Manufacturing Services is committed to providing our contract manufacturing partners with the unsurpassed quality and compliance associated with Bayer during the past 100 years. We are driven to achieve our partners' pharmaceutical manufacturing goals by offering a div ... more
Bayer to acquire Conceptus, Inc.
Bayer intends to broaden its portfolio in the field of contraception. Thus, Bayer HealthCare LLC has signed a merger agreement with Conceptus, Inc. (CPTS), the California, U.S., based developer of the Essure® procedure, the leading non-surgical permanent birth control method, which is sold ... more
New products create optimism for the future
2012 was a very successful year for the Bayer Group. “We continued to grow dynamically and achieved our targets for the Group. All the subgroups posted gains in sales and earnings before special items,” said Bayer CEO Dr. Marijn Dekkers at the Financial News Conference in Leverkusen on Thur ... more
Humboldt Foundation cooperates with Bayer Foundation
The Alexander von Humboldt Foundation and the Bayer Science & Education Foundation will soon be awarding joint research fellowships. Until 2018, the Bayer Foundation will be making around three million EUR available to fund approximately ten Humboldt-Bayer Research Fellowships annually. The ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Pharmaceuticals Corporation
Outstanding specialty care takes constant innovation and dedication. These core values set Bayer HealthCare Pharmaceuticals apart and enable us to offer an industry-leading portfolio of products and support that healthcare providers and their patients require. Bayer HealthCare Pharmaceutic ... more
Bayer Schering GmbH, Leverkusen (formerly Dritte BV GmbH) today informed the Management Board of Schering AG that the cash compensation for the requested transfer of the shares of Schering’s minority shareholders (squeeze-out) has been determined as EUR 98.98 per Schering share. The amount ... more
Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
